PCSS Exchange Session 4 – Prepare, Part 2
Facilitator: Sherry Larkins, PhD, Director of International Programs and Research Sociologist, Integrated Substance Abuse Programs at the University of California, Los Angeles – Semel Institute for Neuroscience and Human Behavior Cost: No fee Target Audience: Physicians, nurse practitioners or other advanced practice nurses, PAs, psychologists, clinical administrators and healthcare teams. Credit Designations Available: AMA PRA […]
PCSS Exchange Session 6 – Implement and Sustain, Part 2
Once we’ve successfully managed the organizational and clinical steps to initiate treatment for patients with OUD, we need to consider how to best sustain this new service and ensure continued access to high-quality care for our most challenging patients. This session will review long-term staffing structure and needs as buprenorphine (or other pharmacotherapies) become part of the treatment landscape in the community. The session will also review the challenges in delivering buprenorphine treatment to a range of patient populations, including those with comorbid mental health and/or physical health conditions, pregnant patients, those with co-occurring pain, and poor responders.
PCSS Exchange Session 5 – Implement and Sustain, Part 1
After the organizational and clinical components of initiating OUD treatment have been mapped out, how do we begin effective implementation? This session will review steps for conducting a small pilot/demonstration buprenorphine project, with regular outcomes-monitoring to ensure a smooth scale up of treatment and care for patients with OUD. We will discuss approaches for utilizing leadership and staff check-ins to get a pulse on practices, scale up, and changes needed to ensure successful expansion across all administrative and clinical staff.
PCSS Exchange Session 4 – Prepare, Part 2
This session will map out concrete clinical and patient flow activities and consider issues of documentation, charting, and recommended metrics. We will discuss steps for conducting a site walk-through in advance to ensure behavioral health and prescriber staff have completed the necessary certifications and trainings to deliver buprenorphine, or other pharmacotherapies, in integrated settings. We will review the range of possible team players – clinic leadership, prescribers, nurses, counselors, clinicians, intake coordinators, receptionists, peer support specialists – and discuss the value of a shared vision and delineation of roles and tasks.
PCSS Exchange Session 3 – Prepare, Part 1
The strengths and barriers for each community and clinic vary, and there is no one-size-fits-all model for implementing medications for addiction treatment (MAT). Questions you have might have include: What models have been used to successfully scale up MAT for OUD patients? What models have specifically been used to scale up buprenorphine treatment? How do we know which model might work best in a particular setting? This session will review these questions and highlight concrete organizational and administrative steps and processes to consider when defining your own clinic’s needs in treatment delivery. We will discuss the value of developing a MAT implementation plan that includes clinical considerations, process improvement considerations, staffing, and financial considerations.
PCSS Exchange Session 2 – Explore, Part 2
Once your clinical site leadership has demonstrated an interest in exploring buprenorphine or other pharmacotherapies as a treatment option for opioid use disorder (OUD) patients, and you have identified a champion to help lead the effort, what are the next steps? How can you ensure the broader clinical workforce is properly trained and confident in their ability to treat patients using pharmacotherapies? This session will review key clinical components of medications for addiction treatment (MAT), including buprenorphine treatment and its various formulations, clinic-wide implementation of new medications, and staff preparation, readiness and motivation. We will also review organizational capacity to access medication, properly screen and identify patients, and engage community partners and referral resources necessary to ensure OUD patients have access to a continuum of treatment and care services.
PCSS Exchange Session 1 – Explore, Part 1
Have you considered prescribing Medications for Addiction Treatment (MAT) to treat your patients with opioid use disorder (OUD)? Have you wondered what is required to prescribe buprenorphine or other pharmacotherapies? If you answered yes to either or both of these questions, this PCSS Exchange session could provide you with the critical information and steps in determining the readiness of your site and clinical leadership. Initiating MAT into your setting requires that you think through the business case for service expansion and strategize how to best engage, identify and motivate site champions and key staff to work with you in the implementation and integration of this clinical service.
